Key result
Combined therapy with lisinopril and avosentan normalized proteinuria, protected from tubulointerstitial damage, and induced regression of glomerular lesions in diabetic rats.
Why the study?
Does the combination of lisinopril and avosentan improve renal lesions in a rat model of diabetic nephropathy?
Population
Uninephrectomized rats made diabetic by streptozotocin with proteinuria
Comparison
Combination of lisinopril and avosentan orally… vs Placebo, lisinopril alone, or avosentan alone
Design
Preclinical
Follow-up
4 months (from 4 to 8 months of age/disease)
Authors
Loading...
Synergistic renoprotection in diabetic rat model; leaves open translation to human diabetic nephropathy.
Does the combination of lisinopril and avosentan improve renal lesions in a rat model of diabetic nephropathy?
The combination of an ACE inhibitor and an ETA receptor antagonist synergistically induces regression of glomerular lesions and tubulointerstitial damage in experimental diabetic nephropathy.
Gagliardini et al. (2009) studied Overt diabetic nephropathy. Lisinopril plus avosentan vs. Placebo, lisinopril alone, or avosentan alone was evaluated on Proteinuria, renal damage, podocyte number, nephrin expression, and glomerular size selectivity. Combined therapy with lisinopril and avosentan normalized proteinuria, protected from tubulointerstitial damage, and induced regression of glomerular lesions in diabetic rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: